8-K current report · filed Oct 5, 2026

STANDARD BIOTOOLS INC. (LAB) 8-K Current Report: October 5, 2026

Item 7.01Item EX-99.1LAB overview

Short answer

STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Definitive agreement to sell Microfluidics business to ARCHIMED, materially reshaping Standard BioTools’ portfolio.

STANDARD BIOTOOLS INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Definitive agreement to sell Microfluidics business to ARCHIMED, materially reshaping Standard BioTools’ portfolio
  • Closing expected in approximately 30 days, subject to customary conditions
  • Transaction could generate proceeds and reduce operating complexity, but financial terms are not included in the filing
  • Completion remains uncertain, with termination fees, competing bids and unmet conditions identified as key risks

Item EX-99.1 · Exhibit EX-99.1

  • Definitive agreement to sell Microfluidics business to ARCHIMED, advancing Standard BioTools’ strategic portfolio reshaping
  • Expected closing in approximately 30 days, subject to customary conditions
  • Microfluidics remains within Standard BioTools until closing, delaying operational and financial separation
  • No sale price or transaction proceeds disclosed, limiting near-term valuation assessment
  • Completion risks include unmet conditions, termination, expenses, or competing acquisition proposals

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other STANDARD BIOTOOLS INC. 8-K filings

Get the next LAB 8-K as it lands

Follow LAB for push alerts, or ask the research agent what this filing means.